Factors Associated with Health-Related Quality of Life in Late-Stage Parkinson’s Disease

Kristina Rosqvist, PhD1,*, Per Odin, MD, PhD1,2, Stefan Lorenzl, MD, PhD3,4, Wassilios G. Meissner, MD, PhD5,6,7,8, Bastiaan R. Bloem, MD, PhD9, Joaquim J. Ferreira, MD, PhD10, Richard Dodel, MD, PhD11, and Anette Schrag, MD, PhD12

the Care of Late Stage Parkinsonism (CLaSP) Consortium

ABSTRACT: Background: There is limited knowledge on health-related quality of life (HRQoL) in late-stage Parkinson’s disease (PD). Objective: To assess factors associated with HRQoL in patients with late-stage PD, with a focus on health care provision. Methods: The Care of Late Stage Parkinsonism (CLaSP) project is the largest study on late-stage PD to date. The current study analyzed data of 401 patients from 6 European countries in whom HRQoL was assessed with the 8-item PD Questionnaire in patients without dementia. Factors potentially associated with HRQoL were assessed and examined in linear regression analyses.

Results: Better HRQoL was associated with living at home, greater independence in activities of daily living (Schwab and England Scale), less severe disease (Hoehn and Yahr stage), better motor function (Unified PD Rating Scale Part III), and lower non-motor symptoms burden (Non-Motor Symptoms Scale [NMSS]) across all NMSS domains. Having a PD specialist as physician for PD, contact with a PD nurse, and no hospital admission during the past 3 months were associated with better HRQoL, but having seen a physiotherapist or occupational therapist was associated with worse HRQoL.

Conclusions: The results emphasize the importance of optimizing treatment for motor and multiple non-motor symptoms to improve HRQoL in patients with late-stage PD. PD-specific health care resources, particularly PD nurses, are likely important in addressing issues to improve HRQoL in this population. Worse HRQoL in those who had recently seen a physiotherapist or occupational therapist may reflect referral based on factors not measured in this study.
nonspecialist clinicians. Despite this, to date there is limited research or guidance on the pharmacological and non-pharmacological management of late-stage PD.3

Previous studies have shown that both motor and NMS affect health-related quality of life (HRQoL) in PD.8 HRQoL is defined as the impact of health status on a person’s quality of life (QoL), a multidimensional concept including physical, mental, emotional, and social functioning.9 A person’s perceived health status provides relevant information about individual functioning and well-being and constitutes an appropriate outcome measure in PD.10 As improving HRQoL is the key aim in PD therapy, particularly in the late stage of the disease, identification of factors associated with patient HRQoL can help address these factors and focus future research to improve HRQoL in late-stage PD. The aim of this study was to describe and assess factors associated with HRQoL in late-stage PD with a special focus on health care provision.

**Patients and Methods**

**Participants and Recruitment**

Baseline data from the longitudinal multicenter cohort study Care of Late Stage Parkinsonism (CLaSP) were used. Details of this study can be found elsewhere.11 Patients were recruited at 7 movement disorder centers in 6 European countries (the United Kingdom, Germany, the Netherlands, Portugal, France, and Sweden) with different health care systems. The goal of the project was to establish a large European cohort of patients in late-stage PD, defined as HY stages IV to V (score range 1–5, higher = worse)2 while on medication and/or having a substantial need of help with ADL; ≤50% on the Schwab and England ADL Scale (score range 0–100, higher = better).12 Patients were identified through various health care settings at the different centers: neurology departments; the municipality-based health care system; and care of the elderly, palliative care, and primary care physicians.11

Inclusion criteria were HY stages IV and V while on medication and/or having a substantial need of help with ADL (≤50% on the Schwab and England Scale)12 as well as having been diagnosed with parkinsonism for a minimum of 7 years. Exclusion criteria were cognitive symptoms that started before the PD diagnosis as well as symptomatic parkinsonism (such as drug-induced parkinsonism or normal pressure hydrocephalus). For this study we only included patients without an established diagnosis of dementia.

**Procedure and Clinical Evaluation**

HRQoL was assessed by the 8-item PD Questionnaire (PDQ-8; score range 0–32, higher = worse), a PD-specific subjective measure of overall health status, which is a shorter form version derived from the PDQ-39. The results of the 2 instruments have been found to be highly similar, and the use of the shorter form has been recommended when a shorter version is needed or preferred.13,14 The PDQ-8 includes 8 items, scored 0 to 4, from the 8 domains of the PDQ-39: mobility, ADL, emotional well-being, social support, cognition, communication, bodily discomfort, and stigma. The scores are summed, divided by the total possible, and given as a percentage score of 100.

Motor function was assessed by the motor part of the Unified PD Rating Scale Part III (UPDRS III, score range 0–108, higher = worse).15 Non-motor symptomatology was assessed by the Non-Motor-Symptoms Scale (NMSS; score range 0–360, higher = worse).16 The NMSS has 30 items that are grouped into 9 domains. Cognitive function was assessed with the Mini-Mental State Examination (MMSE, score range 0–30, higher = better).17 Depressive symptoms were assessed by the Geriatric Depression Scale (GDS-15; score range 0–15, higher = worse).18,19

A study-specific resource utilization questionnaire for patients with PD and their informal caregivers was used to determine the use of health care as well as informal care resources.11,20 A PD specialist was here defined as a neurologist, geriatrician, or elderly care physician. A PD nurse is a nurse who has experience in working with patients with PD.

Information on patients’ medication was collected and levodopa equivalent daily dose (LEDD) was calculated according to a standardized formula.21

**Statistical Analyses**

Descriptive and clinical data are given as median with first and third quartiles (q1–q3) and frequencies and percentages, as appropriate. Associations were tested statistically with simple linear regression analyses. For the multivariable PDQ-8 analyses, 20 independent variables with P values <0.3 from the simple linear regression analyses were simultaneously entered into a multivariable linear regression model to identify factors independently associated with HRQoL. A backward-stepping regression analysis was conducted where P values were inspected and the variable with the highest P value was manually removed from the model, which was repeated until the remaining independent variables in the model had P values <0.1. P values of <0.05 were considered significant. All analyses were performed using IBM SPSS version 26.0 (IBM Corporation, Armonk, NY).

**Results**

**Demographic and Clinical Data**

The study consisted of 401 patients. The number of patients from the different European countries were as follows: United Kingdom, n = 77 (19%); Germany, n = 121 (30%); France, n = 37 (9%); Sweden, n = 73 (18%); the Netherlands, n = 42 (10%); and Portugal, n = 51 (13%). The median (q1–q3) age was
### TABLE 1 Demographic and clinical data of the patients with late-stage PD (n = 401)

| Variables                         | Median (q1–q3) or n (%) | Missing, n |
|-----------------------------------|-------------------------|------------|
| Age, yr                           | 76 (70–81)              | –          |
| Sex, male                         | 216 (54)                | –          |
| PD duration, yr                   | 14 (10–19)              | 2          |
| Age at onset, yr                  | 60 (52–68)              | 2          |
| HY stage                          | 4 (4–4)                 | –          |
| HY stage                          | II–III                  | 32 (8)     |
| IV                                | 286 (71)                | –          |
| V                                 | 83 (21)                 | –          |
| ADL independency, S&E              | 40 (30–50)              | –          |
| Dwelling place                    |                         | –          |
| Home                              | 323 (81)                | 1          |
| Nursing home                      | 78 (19)                 | 1          |
| Partner, yes                      | 262 (66)                | 1          |
| LEDD, mg                          | 825 (550–1195)          | 6          |
| Clinical assessments              |                         |            |
| Motor function, UPDRS III         | 41 (32–54)              | 2          |
| Non-motor symptoms, NMSS          | 87 (56–122)             | 8          |
| Non-motor symptoms, NMSS, domains |                        |            |
| Cardiovascular including falls    | 1 (0–4)                 | 8          |
| Sleep/fatigue                     | 12 (6–20)               | 8          |
| Mood/apathy                       | 9 (4–23)                | 8          |
| Perceptual problems/hallucinations| 1 (0–6)                 | 8          |
| Attention/memory                  | 6 (1–15)                | 8          |
| Gastrointestinal tract            | 10 (4–16)               | 8          |
| Urinary                           | 12 (4–24)               | 8          |
| Sexual function                   | 3 (0–16)                | 8          |
| Miscellaneousc                    | 12 (5–18)               | 8          |
| Cognition, MMSE                   | 26 (24–28)              | 9          |
| Depressive symptoms, GDS-15       | 6 (4–9)                 | 89         |
| Participants per country          |                         | –          |
| United Kingdom                    | 77 (19)                 | 38         |
| Germany                           | 122 (38)                | 38         |
| France                            | 37 (9)                  | 38         |
| Sweden                            | 73 (18)                 | 38         |
| The Netherlands                   | 42 (18)                 | 38         |
| Portugal                          | 51 (13)                 | 38         |
| Physician for PDd                 |                         | 38         |
| GP                                | 202 (56)                | 38         |
| PDspecialist*                     | 112 (31)                | 38         |
| Neurologist                       | 295 (81)                | 38         |
| Geriatrician                      | 285 (79)                | 38         |
| Elderly care physician            | 7 (2)                   | 38         |
| Other/do not know                 | 3 (1)                   | 38         |
| Contact for PD, past 3 mo         |                         | 38         |
| GP                                | 202 (56)                | 38         |
| PDspecialist*                     | 112 (31)                | 38         |
| PDnurse                           | 273 (48)                | 38         |
| Physiotherapist                   | 59 (16)                 | 38         |
| Occupational therapist            | 207 (57)                | 38         |
| Speech and language therapist     | 63 (17)                 | 38         |
| Hospital admitted                 | 78 (22)                 | 38         |
| Rehabilitation center overnight   | 96 (26)                 | 38         |
| Rehabilitation center outpatient  | 21 (6)                  | 38         |
| Help from caregiver in daily life | 11 (3)                  | 38         |
| Health-related quality of life assessment | 304 (84) | 40         |
| PDQ-8f                            | 44 (34–56)              |            |

PD, Parkinson’s disease; q1-q3, first and third quartiles; HY, Hoehn and Yahr; ADL, activities of daily living; S&E, Schwab & England; LEDD, levodopa equivalent daily dose; UPDRS III, Unified PD Rating Scale, Part III, motor examination; NMSS, Non-Motor Symptoms Scale; MMSE, Mini-Mental State Examination; GDS-15, Geriatric Depression Scale; GP, general practitioner; PDQ-8, 8-item PD Questionnaire.

S&E ADL scale score range 0 to 100, higher = better.

HY staging scale score range 1 to V, higher = worse. UPDRS III score range 0 to 108, higher = worse. NMSS score range 0–360, higher = worse. MMSE score range 0 to 30, higher = better. GDS-15 score range 0 to 15, higher = worse. PDQ-8 (PD-specific health measure) score range 0 to 32, higher = worse.

*Nursing home, including long-term institutional care, intermediate forms of accommodation (eg, short-term care/respite care), and assisted living.

Partner includes married, living apart, and partnership. No partner includes single, divorced, and widowed.

Miscellaneous domain includes pain, change in ability to taste or smell, change in weight, and excessive sweating.

There is slight overlap, as some patients see more than 1 category for their PD: neurologist + GP + geriatrician + elderly care physician.

In nondemented patients only.
**TABLE 2** Simple linear regression analyses with PDQ-8 as the dependent variable (n = 401)

| Independent Variables | Unstandardized Coef | 95% CI | P Value | Controlled for Age and Sex |
|-----------------------|---------------------|-------|---------|---------------------------|
| Age, yr               | −0.08 (−0.19 to 0.18) | 0.070 | −       | −                         |
| Male                  | 0.85 (−2.46 to 4.15)  | 0.615 | −       | −                         |
| PD duration, yr       | 0.08 (−0.13 to 0.30)  | 0.459 | 0.08 (−0.14 to 0.29) | 0.465 |
| HY stage              | 2.73 (1.87 to 5.30)   | 0.037 | 2.81 (0.23 to 5.38) | 0.033 |
| ADL independency, S&E| −0.35 (−0.45 to −0.24) | 0.001 | −0.35 (−0.46 to −0.24) | 0.001 |
| Dwelling place, home vs. nursing home | 4.64 (0.52 to 8.75) | 0.027 | 4.91 (0.70 to 9.13) | 0.022 |
| Partner, yes          | 2.22 (−1.24 to 5.68)  | 0.288 | 2.21 (−1.48 to 5.91) | 0.239 |
| Motor function, UPDRS III | 0.36 (0.36 to 0.47) | 0.001 | 0.36 (0.26 to 0.47) | 0.001 |
| NMS, NMSS domains     | Cardiovascular including falls 0.47 (0.11 to 0.82) | 0.010 | 0.47 (0.11 to 0.82) | 0.011 |
|                      | Sleep/fatigue 0.47 (0.32, 0.63) | 0.001 | 0.48 (0.33 to 0.64) | 0.001 |
|                      | Mood/apathy 0.52 (0.42 to 0.62) | 0.001 | 0.53 (0.43 to 0.63) | 0.001 |
|                      | Perceptual problems/hallucinations 0.53 (0.24 to 0.82) | 0.001 | 0.53 (0.24 to 0.82) | 0.001 |
|                      | Attention/memory 0.67 (0.50 to 0.84) | 0.001 | 0.68 (0.51 to 0.85) | 0.001 |
|                      | Gastrointestinal tract 0.57 (0.37 to 0.78) | 0.001 | 0.57 (0.37 to 0.78) | 0.001 |
|                      | Urinary 0.23 (0.09 to 0.36) | 0.001 | 0.23 (0.10 to 0.37) | 0.001 |
|                      | Sexual function 0.48 (0.23 to 0.56) | 0.001 | 0.48 (0.23 to 0.57) | 0.001 |
|                      | Miscellaneous* 0.35 (0.18 to 0.53) | 0.001 | 0.36 (0.19 to 0.54) | 0.001 |
|                      | Physician for PD −4.33 (−8.51 to −0.16) | 0.042 | −3.67 (−8.59 to 1.26) | 0.144 |
|                      | Contact for PD, past 3 mo 1.25 (−2.22 to 4.71) | 0.480 | 1.26 (−2.23 to 4.76) | 0.477 |
|                      | PD specialistb 0.00 (−0.48 to 2.89) | 0.737 | −0.60 (−1.48 to 0.29) | 0.273 |
|                      | PD nurse −8.48 (−13.89 to −3.86) | 0.001 | −8.54 (−13.18 to −3.89) | 0.001 |
|                      | Physiotherapist 6.20 (2.76 to 9.64) | 0.001 | 6.42 (2.92 to 9.93) | 0.001 |
|                      | Occupational therapist 4.59 (0.83 to 9.14) | 0.001 | 4.63 (0.84 to 9.22) | 0.001 |
|                      | Speech/language therapist 4.19 (−0.01 to 8.39) | 0.051 | 4.27 (0.02 to 8.53) | 0.049 |
|                      | Hospital admitted 4.10 (0.19 to 8.01) | 0.040 | 4.19 (0.23 to 8.15) | 0.038 |
|                      | Rehabilitation admitted −1.16 (−6.25 to 8.62) | 0.754 | 1.22 (−6.29 to 8.72) | 0.750 |
|                      | Rehabilitation outpatient −0.27 (−10.39 to 9.85) | 0.958 | −0.26 (−10.45 to 9.92) | 0.960 |

**TABLE 3** Multivariable linear regression analyses with PDQ-8 as the dependent variable (n = 354)

| Independent Variables* | Unstandardized Coef | 95% CI | Standardized Coef | P Value |
|------------------------|---------------------|-------|-------------------|---------|
| Motor function, UPDRS III | 0.22 (0.12 to 0.31) | 0.193 | 0.001 |
| Mood/apathy, NMSS D3 | 0.29 (0.18 to 0.41) | 0.258 | 0.001 |
| Attention/memory, NMSS D5 | 0.27 (0.10 to 0.44) | 0.148 | 0.002 |
| Gastrointestinal tract, NMSS D6 | 0.27 (0.08 to 0.46) | 0.128 | 0.005 |
| Sleep/fatigue, NMSS D2 | 0.21 (0.06 to 0.36) | 0.130 | 0.007 |
| Dwelling place, home vs. nursing home | 4.58 (0.97 to 8.19) | 0.188 | 0.013 |
| PD nurse past 3 mo | −4.42 (−8.26 to −0.58) | −0.985 | 0.024 |
| Physiotherapist past 3 mo | 3.84 (10.39 to 5.94) | 0.089 | 0.040 |

76 (70–81) years and the median (q1–q3) disease duration was 14 (10–19) years. The majority (262; 66%) of the patients had a partner; 323 (81%) of the patients lived in ordinary housing, and 78 (19%) lived in a nursing home. The median (q1–q3) MMSE score was 26 (24–28),
and the median (q1–q3) GDS-15 score was 6 (4–9). The median (q1–q3) LEDD was 825 (550–1195) mg. The median (q1–13) PDQ-8 score was 44 (34–56) (Table 1).

In the simple linear regression analyses, better HRQoL (PDQ-8) was associated with greater independence in ADL (Schwab & England), living at home, a less severe disease stage (HY), better motor function (UPDRS III), lower NMSS scores in all domains, including less severe cardiovascular, sleep/fatigue, mood, hallucinations, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous NMS domain scores (miscellaneous NMSS domain includes pain, change in ability to taste or smell, change in weight, and excessive sweating). Moreover, having a PD specialist as physician for PD, having had contact with a PD nurse during the past 3 months, and not having had any hospital admissions during the past 3 months were associated with better HRQoL, whereas contact with a physiotherapist or occupational therapist during the past 3 months was associated with worse HRQoL (Table 2). A further characterization of patients who had seen a physiotherapist during the past 3 months indicated that they had considerably more NMS, particularly in the areas of sleep/fatigue and mood/apathy, compared with those who had not seen a physiotherapist. When controlling for NMS using the NMSS, there was no longer a significant relationship of HRQoL with having seen a physiotherapist or occupational therapist, but the relationship with having a PD specialist or having seen a PD nurse remained.

The multivariable analyses identified better UPDRS III motor function; lower NMSS scores in the domains of mood, attention/memory, gastrointestinal, and sleep/fatigue; living at home; and having seen a PD nurse in the past 3 months as being associated with better HRQoL (PDQ-8) scores. Contact with a physiotherapist during the past 3 months was associated with worse HRQoL (Table 3).

Discussion

This study from the European multicenter CLaSP project is the first to examine HRQoL in a large cohort of patients with late-stage PD, a vulnerable and very disabled patient group that has thus far received little attention in the literature. The results will contribute to the construction of a knowledge base for future research to help improve HRQoL in these severely afflicted patients.

The clinical PD features of non-motor (NMSS) and motor (UPDRS III) symptomatology both had strong negative associations with HRQoL. This underlines the fact that the foundation for improving HRQoL in late-stage PD involves optimizing the treatment for motor and NMS.5,6,22

Previous studies have shown that NMS are common in late-stage PD,5,23 and that they generally have a greater impact on HRQoL in PD than motor symptoms.24–26 The literature provides particularly strong evidence for an association between depressive symptoms and reduced HRQoL in PD.7,27–32 The present analyses showed that these negative associations between HRQoL and NMS and particularly depressive symptoms continue to be strong in late-stage PD.

In the univariate analysis of the main sample, we also found that greater independence in ADL was associated with better HRQoL, which is in line with previous research in PD26 and in the general population.33,34 Similarly, general self-efficacy has a strong association with life satisfaction in PD.7

We furthermore investigated the associations between specific health care factors and HRQoL. Residing at home was associated with a better HRQoL than residing in a nursing home, similar to what has been found in non-PD populations.35 It was reassuring to find that having recently seen a PD nurse (perhaps reflective of regular reviews) was associated with better HRQoL in a univariate analysis and was among the predictors of the HRQoL scores in the multivariable model. We also found that being followed by a PD specialist was associated with better HRQoL scores in univariate analysis. Previous research also reported that PD specialist care is associated with improved clinical outcomes and greater survival.36 Having had a recent hospital admission was associated with worse HRQoL; whether this was a causal relationship or merely an association cannot be determined from cross-sectional analysis, although it seems likely that having to be admitted to hospital is probably indicative of a more severe disease and overall health and thereby likely also of a poorer QoL. In addition, we found that having seen a physiotherapist or occupational therapist during the past 3 months was associated with worse HRQoL, which we believe is likely to reflect referral of patients with worse overall functioning to this service. This was also suggested by the finding of a higher rate of NMS, particularly in the areas of sleep/fatigue and mood/apathy, in those who had seen a physiotherapist compared with those who had not seen a physiotherapist. When controlling for NMS, the negative association of having seen a physiotherapist or occupational therapist was no longer observed, although the negative association with having seen a physiotherapist persisted in the overall multivariable analysis. It is likely that patients referred to physiotherapy differed in a number of factors affecting the patients’ HRQoL, not all of which we could assess and control for. Motor severity, as assessed by the UPDRS III, was not different between those who had and had not seen a physiotherapist, but as motor severity was high in almost all of the patients, this provided limited information. However, it is likely that patients who experience symptoms that are difficult to treat are referred to physiotherapy, whereas those who are better functioning are not. There is considerable evidence in the literature that physiotherapy is beneficial for the PD population and is essential for maintaining physical function.37,38 We therefore believe that those referred to physiotherapy represent the most severely affected group and that rather than suggesting that physiotherapy has a negative effect in late-stage PD, the referrals were being made because of the associated severe disability. Worse HRQoL in those who had recently seen a physiotherapist or occupational therapist may also reflect referral based on factors not measured in this study.
Nevertheless, this association will need to be examined in prospective studies in matched samples.

Overall, the percentage of scores explained by the variables examined here was 36%. Aspects of life other than those covered by the questionnaires may also affect a person’s HRQoL. Intrinsic factors such as resilience, sense of coherence, and general self-efficacy, which we did not measure in this study, may also be relevant explanatory factors, important for the individual capacity to cope with difficult situations. To support patients adequately for an enhanced HRQoL in late-stage PD, it is likely that individual solutions and resources from a broad spectrum of instances are needed when it comes to both PD-specific and more general health care, including municipality-based health and social care services.

Strengths, Limitations, and Future Perspectives

Across 6 European countries, we successfully included 401 patients in the late and most severe stage of the disease, collecting a substantial amount of information in an area where knowledge was previously limited. As many patients in late-stage PD have considerable difficulties coming to the clinics, we accomplished the inclusion of a high number of participants through a multipronged approach with substantial resource use and often several home visits. Nevertheless, the severity of impairment resulted in some incomplete data with a reduction of the number of participants in the multivariable analysis.

Future studies should continue to investigate and elucidate the symptomatology and the needs of late-stage PD, in order to build a platform of knowledge on which both future research and clinical recommendations can be based. Furthermore, because of the cross-sectional study design, this study cannot provide information on causality. Longitudinal analyses as well as randomized controlled trials will be needed to provide information on the effect of various health care resources and specific treatments.

The results emphasize the importance of optimizing treatment for motor and the range of NMS to improve HRQoL in patients with late-stage PD. PD-specific health care resources, particularly PD nurses, are likely important in addressing issues to improve HRQoL in this population.

Acknowledgments

We thank the patients with late-stage PD and their informal caregivers for their time and effort in participating.

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.

K.R.: 1B, 1C, 2A, 2B, 3A
P.O.: 1A, 1B, 1C, 2A, 2B, 2C, 3B
S.L.: 1A, 1B, 1C, 3B
W.G.M.: 1A, 1B, 1C, 3B
B.R.B.: 1A, 1B, 1C, 3B
J.J.F.: 1A, 1B, 1C, 3B
R.D.: 1A, 1B, 1C, 3B
A.S.: 1A, 1B, 1C, 2A, 2B, 2C, 3B

Disclosures

Ethical Compliance Statement: The study was approved by the ethical review committees of all participating study centers (London: Camden and Islington National Research Ethics Service (NRES) Committee 14/LO/0612; Bordeaux: South West France and Overseas ethics protection committee III 2014/85; Lisbon: Centro Hospitalar Lisboa Norte, DIR-CLIN-19SET2014-275; Lund: The Swedish Ethical Review Authority, Joint Programme – Neurodegenerative Disease Research (JPN) HC 559-002; Marburg: Ethics Commission at the State Medical Association Hesse, MC 309/2014; Munich: ethics committee at the Ludwig Maximilian University of Munich (LMU), 193-14; Nijmegen: Radboud University Medical Center, group staff quality and safety human research committee, Arnhem-Nijmegen region, DJ/CMO300). Written informed consent was obtained by the participants. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest: The study was funded through the Joint Programme–Neurodegenerative Disease Research; through national funding bodies in all 6 countries—United Kingdom: Economic and Social Research Council ES/L009250/1; Sweden: the Swedish Research Council and CLaSP/JPN HC-559-002; Germany: Federal Ministry of Education and Research (BMBF), Marburg, 01ED1403A, Munich, 01ED1403B; France: ANR-13-JPHC-0001-07; Portugal: HC/0002/2012; Holland: 733051003. In addition, the study was funded by MultiPark, the strategic research area for neuroscience at Lund University; the Swedish Parkinson Foundation; the Swedish Parkinson Academy, and the Faculty of Medicine at Lund University. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months: K.R. has no additional disclosures to report. P.O. has received honoraria for lectures and expert advice from AbbVie, BIAL, Britannia, Global Genetics, Plosor, Nordic Infucare, PD Neurotechnology, and Zambon. S.L. has received honoraria for lectures from UCB and AbbVie. W.G.M. has received fees for editorial activities with Springer, has served as advisor for Lundbeck and Biocare, and has received teaching honoraria from UCB as well as research support from The Michael J. Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, the
European Community, the French National Research Agency (ANR), Association for the Research on Multiple System Atrophy (ARAMISE), Progressive supranuclear palsy (PSP-France), Multiple System Atrophy (MSA) Coalition, and the LABEX Excellence Initiative. B.R.B. currently serves as Editor-in-Chief for the Journal of Parkinson’s Disease; serves on the editorial boards of Practical Neurology and Digital Biomarkers; has received honoraria from serving on the scientific advisory board for Zambon, Biogen, UCB, and Walk with Path; has received fees for speaking at conferences from Abbvie, Zambon, Roche, GE Healthcare, and BIAL; and has received research support from the Netherlands Organization for Scientific Research, The Michael J. Fox Foundation, UCB, Abbvie, Zambon, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Medtronic; and has been employed by Faculdade de Medicina de Lisboa and CNS–Campus Neurologico Sénior. R.D. has no additional disclosures to report. A.S. was supported by research grants from Novartis, Fundação Merck Sharp & Dohme (MSD, Portugal), and Medtronic; and has been employed by Faculdade de Medicina de Lisboa and CNS–Campus Neurologico Sénior. M.O. has received honoraria for consultancies from Biogen, Abbvie, Roche, BIAL, and GE Healthcare; and has received grant payments from the University College London (ULCH) Biomedical Research Institute of Health, National Institute for Health Research Unit, the European Commission, Parkinson’s UK, GE Healthcare, and the Economic and Social Research Council; honoraria for consultancies from Biogen, Abbvie, Roche, BIAL, and GE Healthcare; license fee payments from the University College London for the MSA-QoL, PSP-QoL, and PDQ39; and royalties from Oxford University Press.

References

1. Oertel WH. Recent advances in treating Parkinson’s disease. F1000Res. 2017;6:260.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427–442.
3. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012;8(8):435–442.
4. Coelho M, Matti MJ, Toleu E, Ferreira JJ, Valdeolomas F, Rosa M, Sampao C. Late-stage Parkinson’s disease: the Barcelona and Lisbon cohort. J Neurol 2010;257(9):1524–1532.
5. Rosqvist K, Horne M, Hagell P, Ivarsson S, Nilsson MH, Odin P. Levodopa effect and motor function in late stage Parkinson’s disease. J Parkinsons Dis 2018;8(1):59–70.
6. Rosqvist K, Odin P, Hagell P, Ivarsson S, Nilsson MH, Storch A. Dopaminergic effect on non-motor symptoms in late stage Parkinson’s disease. J Parkinsons Dis 2018;8(3):409–420.
7. Rosqvist K, Hagell P, Odin P, Ekström H, Ivarsson S, Nilsson MH. Factors associated with life satisfaction in Parkinson’s disease. Acta Neurol Scand 2017;136(1):64–71.
8. Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M, on behalf of the PICOMS-PD Study Group. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov Disord 2012;27(2):236–241. https://doi.org/10.1002/mds.23961.
9. Balestrino R, Martinez-Martin P. Reprint of "Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease". J Neurol Sci 2017;374:3–8.
10. Martinez-Martin P, Kurtis MM. Health-related quality of life as an outcome variable in Parkinson’s disease. Ther Adv Neurol Disord 2012;5(2):105–117.
11. Balzer-Geldsetzer M, Ferreira J, Odin P, et al. Study protocol: care of Late-stage Parkinsonism (CLxSP): a longitudinal cohort study. BMC Neurology 2018;18(1):185.
12. Schwab R, England A. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham JJ, Donaldson MC, eds. Third Symposium on Parkinson’s Disease. Edinburgh, Scotland: Livingstone; 1969:152–157.
13. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997;26(3):353–357.
14. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman R. The PDQ-8: development and validation of a short-form Parkinson’s disease inventory. Psychol Health 1997;12:805–814.
15. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Vol 2. Trenton, NJ: MacMillan, Healthcare Information FP; 1987:153–163, 293–304.
16. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 2007;22(13):1901–1911.
17. Foltstein MF, Foltstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–198.
18. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17(1):37–49.
19. Sheikh JI, Yesavage JA. Geriatric Depression Scale: recent evidence and development of a shorter version. Clin Gerontol 1986;5:165–172.
20. von Campenhausen S, Winter Y, Rodrigues e Silva A, et al. Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011;21(2):180–191.
21. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25(15):2649–2653.
22. Giugni JC, Okun MS. Treatment of advanced Parkinson disease. Curr Opin Neurol 2014;27(4):450–460.
23. Weerkamp NJ, Tissingh G, Poels PJ, et al. Nonmotor symptoms in nursing home residents with Parkinson’s disease: prevalence and effect on quality of life. J Am Geriatr Soc 2013;61(10):1714–1721. https://doi.org/10.1111/jgp.12488.
24. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, on behalf of the NMSS Validation Group. The impact of non-motor symptoms on quality of life in patients with Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2010;16:292–299.
25. Oertel WH. Recent advances in treating Parkinson’s disease. F1000Res. 2017;6:260.
32. D’Iorio A, Vitale C, Piscopo F, et al. Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson’s disease. Parkinsonism Relat Disord 2017;43:114–117.

33. Solomon R, Kirwin P, Van Ness PH, et al. Trajectories of quality of life in older persons with advanced illness. J Am Geriatr Soc 2010;58(5):837–843.

34. Medhi GK, Sarma J, Pala S, et al. Association between health related quality of life (HRQOL) and activity of daily living (ADL) among elderly in an urban setting of Assam, India. J Family Med Prim Care 2019; 8(5):1760–1764.

35. Olsen C, Pedersen I, Bergland A, et al. Differences in quality of life in home-dwelling persons and nursing home residents with dementia—a cross-sectional study. BMC Geriatr 2016;16:137.

36. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology 2011;77(9):851–857.

37. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis. BMJ 2012;345:e5004.

38. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008;23(5):631–640.

39. Gison A, Rizza F, Bonassi S, Dall’Armi V, Liu N, Guadino S. The sense-of-coherence predicts health-related quality of life and emotional distress but not disability in Parkinson’s disease. BMC Neurol 2014;14:193.